将哌醋甲酯用于癌症相关疲劳？
Putting Methylphenidate for Cancer-Related Fatigue to Rest?
机构信息
Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Division of Palliative Medicine, Department of Medicine, University of Toronto, Toronto, Canada.
出版信息
J Clin Oncol. 2024 Jul 10;42(20):2363-2366. doi: 10.1200/JCO.24.00707. Epub 2024 May 21.
In the article that accompanies this editorial, Stone et al. present a randomized, double-blind, placebo-controlled trial of individually dose-titrated methylphenidate for treatment of fatigue in patients with advanced cancer, finding that methylphenidate, while safe and well-tolerated, was no more effective than placebo at relieving fatigue after 6 (±2) weeks. Future studies should consider the multifaceted nature of cancer-related fatigue, as well as the substantial placebo effects of psychostimulants, and may benefit from focusing on methylphenidate in combination with non-pharmacological interventions, or for fatigue with a predominant emotional or cognitive component.
在随这篇社论发表的文章中，Stone 等人报告了一项针对晚期癌症患者疲劳的个体化剂量滴定哌醋甲酯的随机、双盲、安慰剂对照试验，结果发现哌醋甲酯虽然安全且耐受良好，但在缓解疲劳方面与安慰剂相比并无更好的效果，在 6（±2）周后。未来的研究应考虑到癌症相关疲劳的多方面性质，以及精神兴奋剂的显著安慰剂效应，并且可能受益于专注于哌醋甲酯与非药物干预的结合，或者用于以情绪或认知成分为主的疲劳。
Zotero 插件